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n the pursuit of proﬁ  ts, 
pharmaceutical companies are 
continuously looking to expand the 
market for their products. This article 
examines how Pﬁ  zer transformed 
Viagra from an effective product 
for erectile dysfunction (ED) due to 
medical problems, such as diabetes and 
spinal cord damage, into a drug that 
“normal” men can use to enhance their 
ability to achieve an erection and to 
maintain it (in a “harder” state) for a 
longer period of time. 
    The Rise of Lifestyle Drugs
    An important emerging issue in health 
care is the availability of medications 
to treat what until recently have been 
regarded as the natural results of 
aging or as part of the normal range 
of human emotions. Thus, we now see 
treatments widely advertised for male 
pattern baldness and shyness. Deviating 
even further, drug therapy is moving 
out of treating diseases to providing 
enhancements to what had hitherto 
been seen as normal functioning. This 
evolution in the use of medications has 
introduced dilemmas and controversies 
about what are legitimate conditions 
and treatments for those concerned 
with prescription medications: is any 
deviation from normality fair game for 
treatment? What about people who 
have nothing medically wrong with 
them, but just want to feel better? Who 
will pay for these therapies, and what 
are the implications for the way we use 
health-care resources? 
    Medications that embody these 
controversies are generally referred 
to as lifestyle drugs and perhaps the 
best known of these is sildenaﬁ  l citrate 
(Viagra) This article will examine the 
strategies used by Pﬁ  zer, the maker 
of Viagra, to ensure that the drug was 
seen as legitimate therapy for almost 
any man. Pﬁ  zer took steps to make sure 
that Viagra was not relegated to a niche 
role of just treating men who had ED 
due to organic causes, such as diabetes 
or prostate surgery.
    There is no doubt that Viagra is 
an effective and quite safe drug in 
treating ED secondary to these causes, 
although a systematic review of the 
evidence found that the drug probably 
only results in successful intercourse 
50%–60% of the time [1]. Had Viagra 
been conﬁ  ned to use only in cases 
of ED secondary to organic causes, 
the drug would probably have been a 
modest success for Pﬁ  zer. In order to 
grow the market, Pﬁ  zer had to make 
Viagra the treatment of choice for a 
much wider population of men. The 
perceived prevalence of ED needed to 
be expanded. The impression had to 
be created that ED was of signiﬁ  cant 
concern to many, perhaps even most, 
men or at least those over 40 years 
of age. The criterion of success for 
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treating ED had to be redeﬁ  ned. And 
ﬁ  nally, Viagra had to be seen as an 
important treatment option for men 
with any degree of ED, including rare 
or transitory failures to achieve or 
maintain erections.
  Redeﬁ  ning the Prevalence of ED 
and Its Psychological Effects
    On its Web site, Pﬁ  zer states that “in 
fact, more than half of all men over 40 
have difﬁ  culties getting or maintaining 
an erection” (http:⁄⁄www.viagra.
com/ed/index.asp). The Web site 
does not give a reference to support 
this statement. One possible source 
of support for this statement is the 
Massachusetts Male Aging Study 
(MMAS), a community-based, random 
sample observational survey of men 
aged 40 to 70 years old conducted 
from 1987 to 1989 in cities and towns 
near Boston, Massachusetts [2]. The 
authors of the study extrapolated the 
results to argue that 52% of the entire 
male population in the United States 
between the ages of 40 and 70 suffer 
from ED. The authors stated: “In 
the MMAS sample the prevalence of 
impotence of all degrees was estimated 
at 52%. Projection of these results to 
1990 population data would suggest 
that impotence affects 18 million 
American men 40 to 70 years old” [2]. 
However, the MMAS ﬁ  gures must be 
viewed with a number of caveats. 
    First, there were actually two different 
groups of men in this study. The ﬁ  rst, 
and larger, group answered a series of 
nine questions about sexual activity. 
The second, and much smaller, group 
answered the same nine questions, 
plus an additional question to self-rate 
themselves as not impotent, minimally 
impotent, moderately impotent, or 
completely impotent. The answers to 
this ﬁ  nal question by the men in the 
second group were then applied to 
the ﬁ  rst group to derive the percent 
in the various classes of potency. The 
authors do not provide any information 
about whether the two groups were 
similar, and there are reasons to think 
that differences may exist between the 
groups. The ﬁ  rst group was randomly 
selected from towns and cities in the 
Boston Standard Metropolitan Statistical 
Area [3], while the second group 
was made up of men presenting to a 
university center urology clinic [2]. 
    Even if the scores from one group 
can be transferred to the other, the 
52% ﬁ  gure is still deceptive because 
it doesn’t differentiate ED by age. In 
the MMAS, 40% of 40-year-old men 
had ED, including 17% who were only 
minimally impotent, whereas 67% of 
70 year olds were impotent. Moreover, 
not all studies are in agreement with 
these ﬁ  gures. Analysis of data from the 
US National Health and Social Life 
Survey indicates that among men 50–59 
years old, 18% complained of trouble 
achieving or maintaining an erection 
during the past year [4]. A survey in 
the Netherlands found that only 1% of 
men 50–65 years of age had a complete 
inability to achieve an erection, and it 
was only in men aged 70–78 years that 
the rate of ED was similar to that in the 
MMAS [5]. Out of 13 studies on the 
prevalence of ED that were published 
until June 1998, the MMAS results were 
among the highest [1]. Thus, Pﬁ  zer’s 
statement that “more than half of all 
men over 40 have difﬁ  culties getting 
or maintaining an erection” does 
not reﬂ  ect the large variation in the 
prevalence of ED found in different 
studies. 
    The MMAS found a strong 
association between ED and 
psychological factors, including 
“depression, low levels of dominance, 
and anger either expressed outward 
or directed inward.” The authors 
suggested that psychological symptoms 
might be a cause of ED, but these 
symptoms could also be an effect 
of ED (they wrote that “a man who 
has experienced a recent pattern of 
ED may be expected to be anxious, 
depressed and lacking self-esteem 
and self-conﬁ  dence”) [2]. While not 
to deny that there is an association 
between ED and psychological 
symptoms, once again the MMAS 
may be an outlier. In the Dutch study 
previously mentioned, only one-third of 
all men and only 20% of men over the 
age of 70 with signiﬁ  cant ED had major 
psychological concerns. Furthermore, 
in sexually active men, 17%–28% had 
no normal erections, indicating that 
full erectile function is not essential 
for sexual functioning [5]. Only 20% 
of Japanese men 40 to 79 years of age 
reported more than little worry and 
concern about sexual functioning, 
suggesting that perceptions of elderly 
male sexual function and its impact on 
health-related quality of life may differ 
among cultures and ethnic groups with 
differing values [6]. 
    On its Web site, Pﬁ  zer states: 
“VIAGRA can work for you. In fact, 
studies show that VIAGRA works for 
more than 80% of men with ED taking 
VIAGRA 100 mg versus 24% of men 
taking a sugar pill” (http:⁄⁄www.viagra.
com/whyViagra/highlyEffective.asp). 
The 80% success rate that Pﬁ  zer quotes 
for Viagra is important, though not 
critical, to being able to promote its 
use to a wide variety of men. But that 
number is qualiﬁ  ed on the Pﬁ  zer Web 
site as the number who experience 
improved erections (http:⁄⁄www.viagra.
com/consumer/aboutViagra/index.
asp). It is open to speculation whether 
the goal of most men is improved 
erections, or successful intercourse and 
the achievement of an orgasm. In most 
studies on Viagra, a 50%–60% rate of 
successful intercourse is recorded (in 
the dose titration studies reviewed in 
[1] for patients taking placebo, up to 
25% of attempts at intercourse were 
successful compared with 50%–60% for 
patients taking Viagra 25–100 mg). This 
50%–60% rate is far short of the “more 
than 80% of men” that Pﬁ  zer trumpets.
    Viagra for Any Degree of ED
    To make Viagra into a lifestyle drug, 
Pﬁ  zer needs to convince men that it 
is the ﬁ  rst choice for therapy for any 
degree of ED, whatever the genesis of 
the problem. However, drug therapy 
may not always be the most appropriate 
treatment option. The National Health 
and Social Life Survey data indicate 
that emotional and stress-related 
problems such as a deteriorating 
social and economic position generate 
elevated risk of experiencing sexual 
difﬁ  culties. In these cases, Viagra may 
be less important than counseling 
or help in ﬁ  nding a new job. These 
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possibilities are never mentioned on 
the Viagra Web site. Here is a sample 
of the questions and answers on the 
“About ED” portion of the Web site:
    Question: “I don’t have ED because 
the problem doesn’t happen often. 
Does this mean that VIAGRA is not for 
me?” 
    Answer: “Even if erection problems 
happen only once in a while, VIAGRA 
can help. You should know that most 
men with ED only experience problems 
some of the time. In one study, 
VIAGRA helped 87% of men with mild-
to-moderate ED have better erections 
versus 36% of men taking a sugar pill” 
(http:⁄⁄www.viagra.com/faqs/faqs2.
asp).
    In case the message is missed, there 
is a couple on the Web page where the 
man looks to be in his mid-to-late 30s. 
Pﬁ  zer reinforces its message with direct-
to-consumer magazine ads, such as one 
featuring a virile looking man around 
40 saying, “A lot of guys have occasional 
erection problems. I chose not to 
accept mine and asked about Viagra.” 
    The initial television ads in the US 
for Viagra used an aging Bob Dole 
(born 1923) as a spokesman, a 1996 
Republican presidential candidate. 
Since then, Pﬁ  zer has refocused its 
advertising campaign to match the 
lifestyle message on its Web site. There 
is now advertising of Viagra at NASCAR 
races, and Pﬁ  zer hired 39-year-old 
Rafael Palmeiro, a former Texas 
Ranger baseball player as a spokesman 
(Figure 1) [7]. Pﬁ  zer teamed up with 
  Sports Illustrated   magazine to create the 
Sportsman of the Year Trivia Game 
(http:⁄⁄www.viagra.com/sports/index.
asp). Between 1999 and 2001, Pﬁ  zer 
spent over US$303 million in direct-to-
consumer advertising to get its message 
about Viagra to men [8–10]. Besides 
the large promotion budget, Pﬁ  zer has 
also paid a number of doctors to act as 
“consultants,” delivering public lectures 
and appearing in the mass media to 
expound on ED and Viagra [11] 
    Pﬁ  zer denies that it is targeting 
younger men or that it is positioning 
Viagra as a lifestyle drug. Mariann 
Caprino, a spokeswoman for the 
company, is quoted in the   New York 
Times   as saying, “Have we gone out and 
given our advertising agency instructions 
to speak to this young population? 
No, we haven’t” [7]. But the message 
from the pictures on the Web site, 
in magazine ads, and from people 
like Rafael Palmiero is that everyone, 
whatever their age, at one time or 
another, can use a little enhancement; 
and any deviation from perfect erectile 
function means a diagnosis of ED and 
treatment with Viagra. Increasingly, the 
age proﬁ  le of men using Viagra reﬂ  ects 
the younger audience that Pﬁ  zer denies 
it is targeting. Between 1998 and 2002 
the group showing the largest increase 
in Viagra use was men between the ages 
of 18 and 45, and only one-third of these 
men had a possible etiologic reason for 
needing Viagra [12]. 
    Economic and Social Implications 
of the Expanding Market for 
Lifestyle Drugs
    Drug companies have identiﬁ  ed 
lifestyle drugs as a “growth market.” 
The problems that they are designed 
to treat are easily self-diagnosed—we 
can all see if we are bald or fat—and as 
the baby boomers age, the population 
looking to these drugs will continue to 
grow. Drug companies, driven by proﬁ  t, 
go where the money is. 
    Because of the potential size of 
the market for Viagra, paying for it 
in unlimited quantities will be very 
expensive. Viagra may only be the tip of 
the iceberg. If we believe the prophets 
of technology, soon there will be drugs 
for memory enhancement and the 
possibility of genetic manipulation to 
make us taller or to keep a full head 
of hair. Here we come back to the 
enhancement debate. Do we accept our 
limitations with grace, or is it legitimate 
to seek technological solutions for 
them? In one corner is the view of 
health as freedom from disease, where 
“the central purpose of health care is 
to maintain, restore, or compensate 
for the restricted opportunity and 
loss of function caused by disease 
and disability” [13]. In this model, a 
just medical system would not cover 
treatments and interventions that aim 
to enhance abilities not affected by 
disease and disability. Opposing this 
is an expansionist deﬁ  nition, such as 
the one offered by the World Health 
Organization, where health is “a state 
of complete physical, mental and 
social well-being” (http:⁄⁄www.who.
int/about/deﬁ  nition/en/print.html). 
If we accept this view, then are we not 
obliged to provide for people who want 
to enhance themselves so that they can 
achieve mental and social well-being? 
    This debate is further complicated 
because there is not an equal balance 
in how we look at the options of 
accepting limitations and seeking 
enhancement. In a market-driven 
world, the money is in promoting 
enhancements, not in accepting 
limitations. The ad featuring the 
man who chooses not to accept even 
occasional erection problems is one 
example of how commercial pressures 
bias the debate [14].
    Because of the possibility that large 
numbers of men would request Viagra 
from their doctors, getting insurance 
companies to pay for Viagra presented 
Pﬁ  zer with special problems. Early 
on, Kaiser Permanente refused to 
cover Viagra for its 9 million members 
because of costs expected to be in 
the range of US$100 million per year 
[11]. According to one interpretation, 
reactions from insurers such as Kaiser 
Permanente were the reason that Pﬁ  zer 
put in place a US$35 million campaign 
to change insurers’ decisions [11]. 
Another goal of Pﬁ  zer’s campaign was 
to make ED an acceptable topic for 
public discourse, in order to remove 
the stigma attached to it and increase 
the possibility that third parties would 
provide coverage.
  Conclusion
    Viagra presents a microcosm of 
the debate surrounding drugs that 
enhance lifestyle choices. The drug 
is effective and safe for people 
with medical problems warranting 
treatment, but it also can be used 
by a much wider population. The 
company that manufactures the drug, 
recognizing that the potential market 
is huge, has aggressively targeted 
that much larger community. Pﬁ  zer’s 
well-ﬁ  nanced campaign was aimed at 
raising awareness of the problem of 
ED, while at the same time narrowing 
the treatment possibilities to just a 
single option: medication. Having 
succeeded in turning Viagra into a 
consumer product, Pﬁ  zer then turned 
its attention to payers in order to reap 
the beneﬁ  ts of the expanded market. 
    Ultimately, there must be a debate 
about how limited resources for health 
care should be spent and who should 
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